Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Transplant Proc. 2023 May;55(4):1095-1097. doi: 10.1016/j.transproceed.2023.03.057. Epub 2023 Apr 25.
Polycystic liver disease (PLD) is characterized by the progressive development of polycystic lesions in the kidney and the liver, possibly resulting in dual organ failure. We indicated living donor liver transplantation (LDLT) for a patient with end-stage liver and kidney disease (ELKD) due to PLD on uncomplicated chronic hemodialysis.
A 63-year-old man with ELKD and uncontrolled massive ascites due to PLD and hepatitis B on uncomplicated chronic hemodialysis was referred to us with a single possible 47-year-old female living donor. Because of the necessity of right lobe liver procurement from this small middle-aged donor and uncomplicated hemodialysis on this recipient, we considered LDLT, rather than dual organ transplantation, could be the most well-balanced option to save the life of this recipient with acceptable risk limits for this donor. A right lobe graft with 0.91 for graft recipient weight ratio was implanted with an uneventful operative procedure under intra- and postoperative continuous hemodiafiltration. The recipient was rescheduled on routine hemodialysis on day 6 after transplantation and recovered with a gradual decrease in ascites output. He was discharged on day 56. He continues to have a very good liver function and quality of life without ascites and uncomplicated routine hemodialysis 1 year after transplantation. The living donor was discharged 3 weeks after surgery and is also doing well.
Although combined liver-kidney transplantation from a deceased donor could be the best option for ELKD due to PLD, LDLT can also be an acceptable option for ELKD with uncomplicated hemodialysis, considering the double equipoise theory for both lifesaving of the recipient and acceptable donor risk.
多囊肝病(PLD)的特征是肾脏和肝脏中多囊病变的进行性发展,可能导致双器官衰竭。我们对一名接受非复杂性慢性血液透析的终末期肝肾功能障碍(ELKD)合并多囊肝病(PLD)的患者进行了活体供肝肝移植(LDLT)。
一名 63 岁男性,因 PLD 和乙型肝炎,在非复杂性慢性血液透析过程中出现不可控制的大量腹水导致 ELKD,我们收治了这名患者,他有一位合适的 47 岁女性单合子活体供者。由于从这位小龄中年供者获取右半肝以及接受透析的受者没有合并症,我们考虑 LDLT,而不是双器官移植,可能是挽救这名受者生命的最佳平衡选择,因为供者的风险限制可以接受。一个右半肝移植物的供受者体重比为 0.91,在术中及术后持续进行血液透析滤过的情况下,手术过程顺利。受者在移植后第 6 天重新开始常规血液透析,腹水逐渐减少,逐渐恢复。他在第 56 天出院。他在移植后 1 年仍然保持着非常好的肝功能和生活质量,没有腹水,也没有进行非复杂性常规血液透析。活体供者在手术后 3 周出院,情况良好。
尽管对于 PLD 导致的 ELKD,来自已故供者的联合肝肾移植可能是最佳选择,但考虑到受者的挽救生命和可接受的供者风险的双重平衡理论,对于接受非复杂性血液透析的 ELKD,LDLT 也可以是一种可接受的选择。